Gene therapy and rare diseases
3 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
“Gene therapy appears in top keywords, supported by projects like PRO-CF-MED (cystic fibrosis oligonucleotide therapy) and CorticALS (ALS treatment strategies).”
FR401 projects - MEDIZINISCHE HOCHSCHULE HANNOVER
German medical university strong in gene therapy, cardiac tissue engineering, and lung disease, translating lab research into advanced patient therapies.
“Central to projects RECOMB (SCID gene therapy), CureCN (AAV liver gene therapy), SCIDNET, and the European Joint Programme on Rare Diseases (EJP RD).”
PrimaryDE44 projects - UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU
Polish medical university combining cardiovascular clinical trial expertise with growing medical data science and AI capabilities for heart disease research.
“RECOMB investigated stem-cell based gene therapy for recombination-deficient SCID, indicating capacity in advanced therapy medicinal products.”
PL7 projects